Clinical stage AI drug discovery company Exscientia has appointed a new executive vice president of strategic alliances.
Dr Richard Law joins from Evotec where he was senior vice president of business development for more than seven years and previously head of computational chemistry.
Prior to Evotec, Law was a senior computational chemistry researcher at the University of California, San Diego and Lawrence Livermore National Laboratories. He is also a director on the board of OpenEye Scientific Software.
Law said: “I am tremendously excited to join Exscientia, who have pioneered the use of AI and automation for drug discovery globally.
“Exscientia have demonstrated they can use AI to create drugs with custom-optimised profiles and then move them into the clinic. Adoption of AI to more rapidly bring better medicines to patients is a necessary step change for the industry.”
Professor Andrew Hopkins, CEO of Exscientia, added: “Richard has extensive expertise in biopharma business development, as well as a deep understanding of Exscientia from his research at some of the top computational chemistry laboratories in the world.
“Richard has the experience and relationships to substantially expand Exscientia’s collaborations using our Centaur AI-driven discovery and design platform.”
Healthcare innovators and leaders honoured at Imprivata HealthCon user group and awards ceremony
Wearable communication system may reduce digital health divide
Molecule trains the immune system to prevent cancer
Diabetes patients urged to use fitness games with caution
Urgent work needed to tackle ‘substantial’ digital health inequality
eSight: “The technology has the potential to change someone’s life”
Microsoft invests £2.5 billion in UK AI
TMS shows promise in tackling depression ‘epidemic’
AI depression app set for NHS clinical trial
UK Biobank releases world’s largest single set of sequencing data
- News3 weeks ago
Why a leading healthcare CEO sees recombinant DNA as a metaphor for developing breakthrough technologies
- AI6 days ago
AI model predicts breast cancer risk without racial bias
- Medtech4 weeks ago
Surtex Instruments to unveil game-changing Infinex microsurgery instruments at MEDICA
- AI2 weeks ago
Humans make better cancer treatment decisions than AI, study finds